<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11139311</article-id><article-id pub-id-type="pmc">2363627</article-id><article-id pub-id-type="pii">6691543</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Malingr&#x000e9;</surname><given-names>M M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beijnen</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rosing</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Koopman</surname><given-names>F J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jewell</surname><given-names>R C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>E M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Huinink</surname><given-names>W W Ten Bokkel</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schellens</surname><given-names>J H M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands</aff><aff id="aff2"><label>2</label>Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, Amsterdam, EC, 1066, The Netherlands</aff><aff id="aff3"><label>3</label>Glaxo Wellcome, Research Triangle Park, Five Moore Drive, NC, 27709, USA</aff><aff id="aff4"><label>4</label>Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, Utrecht, CA, 3584, The Netherlands</aff><pub-date pub-type="epub"><day>01</day><month>01</month><year>2001</year></pub-date><pub-date pub-type="ppub"><month>01</month><year>2001</year></pub-date><volume>84</volume><issue>1</issue><fpage>42</fpage><lpage>47</lpage><history><date date-type="received"><day>22</day><month>05</month><year>2000</year></date><date date-type="rev-recd"><day>31</day><month>08</month><year>2000</year></date><date date-type="accepted"><day>13</day><month>09</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp). We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration of the P-gp blocker cyclosporin A (CsA). Now we tested the potent alternative orally applicable non-immunosuppressive P-gp blocker GF120918. Six patients received one course of oral paclitaxel of 120 mg/m<sup>2</sup> in combination with 1000 mg oral GF120918 (GG918, GW0918). Patients received intravenous (i.v.) paclitaxel 175 mg/m<sup>2</sup> as a 3-hour infusion during subsequent courses. The mean area under the plasma concentration&#x02013;time curve (AUC) of paclitaxel after oral drug administration in combination with GF120918 was 3.27 &#x000b1; 1.67 &#x003bc;M.h. In our previously performed study of 120 mg/m<sup>2</sup> oral paclitaxel in combination with CsA the mean AUC of paclitaxel was 2.55 &#x000b1; 2.29 &#x003bc;M.h. After i.v. administration of paclitaxel the mean AUC was 15.92<sup>&#x02008;</sup>&#x000b1; 2.46 &#x003bc;M.h. The oral combination of paclitaxel with GF120918 was well tolerated. The increase in systemic exposure to paclitaxel in combination with GF120918 is of the same magnitude as in combination with CsA. GF120918 is a good and safe alternative for CsA and may enable chronic oral therapy with paclitaxel. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>paclitaxel</kwd><kwd>oral administration</kwd><kwd>bioavailability</kwd><kwd>P-glycoprotein</kwd><kwd>GF120918</kwd></kwd-group></article-meta></front></article>


